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USE OF PAIRED SERUM SAMPLE FOR THE DIAGNOSIS OF Toxoplasma 
INFECTION IN SELECTED POPULATION BY USING ELECSYS TOXO 
IgG/IgM ASSAY IN HUSM 
 
Introduction 
Toxoplasmosis is one of the most common worldwide parasitic infection due to 
Toxoplasma gondii, an obligate intracellular parasite. The mode of transmission is 
through consumption of food or water or undercooked meat  contaminated  with the 
parasite. Maternal infection with vertical transmission depends on age of gestation. 
Severity of infection is during early gestation, may lead to intense complications such as 
intrauterine death (IUD) or later with increased risk of congenital infection. In ocular 
toxoplasmosis, reactivation of infection are common among immunocompromised and 
immunocompetent patients. Serology is still the mainstay for the diagnosis of 
Toxoplasma infection. Therefore, this method  was applied  with paired serum sample in 
selected population using Elecsys Toxo IgG/IgM assay in HUSM. The paired serum 
sample was to classify the infection into early, acute, reactivation, recent, latent, 
possible congenital infection and passive immunity from mother. This study aimed to 
describe the clinical manifestation, determine  the seroprevalence classification of 
infection among the selected populations, validity of the test and percentage of patient 






This is a prospective cohort study held in Microbiology Laboratory, Hospital Universiti 
Sains Malaysia. Paired serum sample with interval of 2 weeks for clinically suspected 
cases among selected populations were collected from 1st January 2016 till 31st 
December 2016.  Elecsys and cobas e 601 analyser was used to perform the Elecsys 
Toxo IgG/IgM ECLIA assay. The classification of infection was generated based on the 
study flow chart. Patients clinical data were obtained from clinical notes or folders. 
 
Results 
A total of 482 patients with paired serum sample were included in the study. The 
highest seroprevalence was in latent infection, 54%.  New born or infants were majority 
having passive immunity from mother and 4.3%  were classified into possible 
congenital infection. Ocular toxoplasmosis were mainly classified into reactivation and 
latent infection. Acute infection was successfully detected especially among new born, 
pregnant women and immune compromised patients. Paired serum sample were 
compared  to clinically confirmed cases as gold standard have given  high  sensitivity  
(100%), low specificity (77.1%),high negative predictive value (NPV) (100%), and low 
positive predictive value (PPV) (53.5%). The ROC curve analyses of paired serum 
sample  showed (AUC) was 0.932 (95% confidence interval between 0.802 and 1.000, p 
– value 0.001). Majority of patients classified into early, acute and reactivation of 







Paired serum sample using Elecsys Toxo IgG/IgM assay is a potential  diagnostic  test  
for Toxoplasma infection due to high sensitivity and specificity. Furthermore is  a good 
tool to classify the infection among selection populations. The classification of infection 
is mainly to provide a better understanding regarding the infection and guide the 


















PENGGUNAAN  SAMPEL SERUM BERPASANGAN  UNTUK DIAGNOSIS  
JANGKITAN Toxoplasma DI KALANGAN POPULASI TERPILIH  DENGAN 
MENGGUNAKAN UJIAN ELECSYS TOXO IgG / IgM DI HUSM  
 
Pengenalan 
Toxoplasmosis adalah salah satu daripada  jangkitan parasit  yang paling mudah 
ditemui. Penyakit ini   disebabkan oleh Toxoplasma gondii, sejenis  parasit intraselular 
obligat. Cara penyebarannya   adalah melalui pengambilan  makanan atau minuman 
serta  daging yang kurang masak  tercemar dengan parasit tersebut. Di samping itu, 
jangkitan daripada ibu kepada anak dalam kandungan  boleh terjadi dan bergantung 
pada usia kehamilan. Jangkitan di awal kehamilan boleh membawa kepada komplikasi 
yang parah seperti kematian janin dalam kandungan, Dalam kes toxoplasmosis okular, 
kebiasaannya terjadi reaktivasi jangkitan di kalangan pesakit kurang daya tahan tubuh 
termasuk  yang sihat juga. Serologi masih menjadi ujian utama bagi tujuan diagnosis 
jangkitan toxoplasmosis. Oleh itu, serologi digunakan dengan sampel serum 
berpasangan dalam populasi terpilih dengan menggunakan ujian Elecsys Toxo IgG / 
IgM di HUSM. Sampel serum yang berpasangan adalah untuk mengklasifikasikan 
jangkitan ke awal, akut, reaktivasi, jangkitan terkini, jangkitan latensi, kemungkinan 
jangkitan kongenital dan imuniti pasif dari ibu. Kajian ini bertujuan untuk 
menggambarkan manifestasi klinikal, menentukan kelaziman klasifikasi jangkitan di 
kalangan populasi terpilih, kesahihan ujian sampel serum berpasangan  dan peratusan 






Kajian kohort prospektif telah  dijalankan di Makmal Mikrobiologi, Hospital Universiti 
Sains Malaysia. Sampel serum yang  berpasangan dengan selang 2 minggu untuk kes 
yang disyaki secara klinikal di kalangan populasi terpilih telah dikumpulkan dari 1 
Januari 2016 hingga 31 Disember 2016. Mesin analisis Elecsys dan cobas e 601 
digunakan untuk melakukan ujian Elecsys Toxo IgG / IgM ECLIA. Klasifikasi 




Sejumlah 482 pesakit dengan sampel serum berpasangan  dimasukkan dalam  kajian ini. 
Klasifikasi   jangkitan yang tertinggi adalah jangkitan latensi, 54%. Bayi baru lahir  
majoriti  mempunyai imuniti pasif dari ibu dan  hanya  4.3% diklasifikasikan ke dalam  
jangkitan kongenital. Kebanyakan kes toxoplasmosis okular  diklasifikasikan ke dalam 
reaktivasi dan jangkitan latensi terutamanya di kalangan pesakit kurang daya tahan 
tubuh dan juga yang sihat. Jangkitan akut telah berjaya dikesan  di kalangan bayi yang 
baru lahir, ibu mengandung dan pesakit kurang daya tahan tubuh. Sampel serum yang 
berpasangan berbanding dengan  kes yang disahkan secara klinikal berdasarkan 
kepiawaian  telah memberikan sensitiviti yang tinggi (100%), spesifisiti yang rendah 
(77.1%), nilai ramalan negatif (NPV) yang tinggi (100%) dan nilai ramalan positif  
(PPV) yang rendah (53.5%). Analisis lengkung ROC sampel serum berpasangan 
menunjukkan (AUC) adalah 0.932 (selang keyakinan 95% antara 0.802 dan 1.000, p - 
nilai 0.001). Majoriti pesakit yang diklasifikasikan kepada  jangkitan awal, akut dan 





Sampel serum berpasangan menggunakan Elecsys Toxo IgG /IgM adalah ujian  
diagnostik yang berpontensi untuk jangkitan Toxoplasma kerana menunjukkan 
sensitiviti dan spesifisiti yang tinggi serta mampu mengklasifikasikan jangkitan di 
kalangan populasi terpilih. Tujuan wujudnya klasifikasi jangkitan Toxoplasma  adalah 
untuk memberi pemahaman yang lebih terperinci mengenai jangkitan itu sendiri dan 





1.1. Background of the study 
Toxoplasmosis is a common worldwide infection caused by the parasite Toxoplasma 
gondii. Approximately 25 to 30% of the world’s human population is infected by 
Toxoplasma gondii (T. gondii) (Montoya and Liesenfeld, 2004). This obligate 
intracellular parasite can invade various types of human cells as well as all warm-
blooded animals, including mammals and birds. The majority of horizontal 
transmissions to humans is caused either by the ingestion of tissue cysts in infected 
meat or by the ingestion of soil, water, or food contaminated with sporulated oocysts 
derived from the environment or, less frequently, directly from cat feces. The 
seroprevalence of toxoplasmosis was estimated to vary from <2% up to 70% in the 
Southeast Asian population (Nissapatorn, 2007). Higher prevalence observed in tropical 
countries with humid and warm climate as similar to Malaysia. 
The seroprevalence of toxoplasmosis in Malaysia among general healthy population is 
20% to 30% (Nissapatorn et al., 2002; Shamilah et al., 2001).  The disease has been 
recognised to be a major cause of morbidity in congenital infection as a result of 
primary acquired maternal infection during gestation and also among 
immunocompromised patients. The seroprevalence of toxoplasmosis in pregnant 
women is significantly increasing with estimation of 27.9% to 49.0%. The frequency of 
seroprevalence according to trimester of pregnancy is increasing, 1st trimester is 33.3% 
, 2nd trimester 45.2% and 3rd trimester  49.0% (Khairul Anuar et al., 1991; Nissapatorn 
et al., 2003b).  
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The frequency of foetal infection increases with gestational age but risk of serious foetal 
anomalies and   prenatal death occurs in early maternal infection. There was one study 
conducted   among 405 congenitally defective Malaysian infant age 0 – 4 month old, 
showed 2% positivity   for toxoplasmosis. In a different study, a total of 8.2% 
intrauterine toxoplasmic infection  per 1000 live births detected with one third presented 
with liver, eye and brain damage (Tan and Mak, 1985). Among immunocompromised 
patients, reactivation of toxoplasmosis encephalitis (TE) is the  most common 
opportunistic infection. Anti-Toxoplasma IgG antibody by ELISA technique shows 
prevalence 41.2% (301) (Nissapatorn et al., 2003a). Congenital ocular toxoplasmosis 
with cicartical stage 63.3%  as  the most common presentation and chronic congenital 
infection with acute recurrences 36.7% occurs below 40 years old, (Lim and Tan, 1983). 
A total of 134 patients with 72% were seropositive for Toxoplasma infection, with most 
apparent symptoms of chorioretinitis and vitritis both having 100% correlation with 
seropositivity (Zurainee et al., 2017). In a study, patients with ocular diseases  showed 
that 12.5 to 31.1% (IgG) and 3.1 to 19.3% (IgM) of toxoplasmosis prevalence were 
found in Malaysia and Thailand (Nissapatorn, 2007).  
The strategies  for diagnosis of toxoplasmosis infection depends on the immune status 
of the patient and clinical setting especially among pregnant women, new born and 
immunocompromised patients. Nowadays, serological tests stands as  primary approach 
and most clinical laboratories uses ELISA for the routine screening of  T. gondii - 
specific IgG and IgM, whereas other techniques are mostly reserved for reference 
laboratories (Robert-Gangneux and Dardé, 2012). Presence of T.gondii specific- IgM 
antibody indicates  acute or recent infection where else a positive IgG indicates a past  
or latent infection and provide immunity to reinfection (Remington et al., 2001; Wong 
and Remington, 1994). By understanding the kinetic of antibody response and the need 
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of precise diagnosis for Toxoplasma infection in in our setting, the requirement for  
paired serum at 2 weeks interval was made available during  this study. It is to establish 
the seroconversion of (IgM and/ or  IgG) and  significant rise or 4 fold rise of Ig G 
antibody titer. Confirmation is still by molecular testing but due to lack of facilities, 
laborious and expensive, serology remains as a screening test and by this study a better 
accuracy for age of infection is made.  
Elecsys and cobas e 601 analyser was used to perform the Elecsys Toxo IgG / IgM  
electro chemiluminescence immunoassay (ECLIA) technique. This  assay was used to 
detect the in vitro quantitative   IgG and IgM   antibodies respectively to T. gondii in 
human serum. During the acute phase of infection, the dominant surface protein on 
tachyzoites is SAG 1 (surface antigen 1), formerly called p30 are highly immunogenic 
properties of SAG 1 induces IgM as well as IgG specific antibodies.  
1.2. Rationale of the study 
Congenital infection is the most important part of the disease burden due to Toxoplasma  
infection in human (Robert-Gangneux and Dardé, 2012). The severity of infection 
depends on age of gestation and the risk of vertical transmission to foetus. In new born, 
presences of IgG antibody explains the passive immunity from mother whom has 
previous exposure to Toxoplasma infection (Lago et al., 2014). Among 
immunocompromised patients with reactivation of infection,  IgM antibodies are  rarely 
found  (Roth et al., 1994).  
However, in  IgM  positive cases, it is important to establish whether the infection is 
acute or recent because IgM antibody may persist over a year (Meek et al., 2001; 
Montoya and Liesenfeld, 2004). Apart from IgM antibodies, another way to appreciate 
the age of infection is to analyse the IgG titer (Robert-Gangneux and Dardé, 2012). 
Thus, the presences of  IgG and /or IgM Toxoplasma antibodies in a single serum 
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sample may suggest but not clarify or define whether the infection was early, acute, 
recent, reactivation or latent infection and passive immunity from maternal (Remington 
et al., 2001). 
Serological test as a screening tool  for Toxoplasma infection has been  routinely done  
in our department. Since last year a new analyser e cobas 601 was introduced  using 
Elecsys Toxo IgG / IgM  electrochemiluminescence immunoassay (ECLIA). This 
analyser provides a cut off value for reactive, indeterminate or nonreactive and also titer  
for semiquantitative calculation. Therefore, the product information recommended to 
take second  sample at 2 weeks interval to establish the seroconversion of ( IgM and/ or  
IgG) and significant rise or  4 fold rise of IgG antibody titer.  Consequently, this 
recommendation was circulated to the wards in the form of  ‘Surat Pekeliling’ to request 
for second sample at 2 weeks interval (Appendix A). The importance of paired serum 
sample, compared to single serum sample is to classify the infection  into early, acute, 
reactivation, recent, latent, passive immunity from mother and possible congenital 
infection.  
The benefits from these classification of Toxoplasma infection by routine serological 
screening is to  provide an early detection of early, acute, recent, reactivation of 
infection especially in congenital toxoplasmosis and pregnant women. This 
classification is very crucial among pregnant women in initiation of treatment  and 
intervention in management.  Whereas for  new born  and infants, the presence of IgG 
antibody in their blood confirms as a passive immunity from mother and long term  
repeated follow up for blood taking can be avoided. Among immunocompromised 
patients, cerebral toxoplasmosis is a major concern as a reactivation of latent infection. 
Significant high titer of IgG antibody without presences of IgM, supported with 
radiological imaging assures the infection and guides the clinician to start treatment 
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without delay. In summary, this classification will assist physician in the treatment of 
toxoplasmosis in those patients. 
1.3.  Literature review 
 Toxoplasma gondii 
Toxoplasma gondii   is an obligate intracellular protozoan responsible for a common 
parasitic infections throughout the world. It was classified in the coccidian subclass, 
phylum Apicomplexa, class Sporozoasida, order Eucoccidiorida, and family 
Sarcocystidae (Frenkel, 1990). Only in the late 1960s the discovery of cat as a definitive 
host and spreading the oocysts through feces was acknowledged. The importance of 
toxoplasmosis in human, was discovered through a congenital infection  and the whole 
spectrum of disease was revised by (Weiss and Dubey, 2009). Recently a breakthrough 
in the evolution of T. gondii has brought us to the understanding of particular virulences 
associated with some genotypes (Mercier et al., 2011). 
 Three parasitic stages   
 The three parasitic stages are rapidly dividing tachyzoites, slowly dividing bradyzoites 
in tissue cysts and sporozoites which are protected in an oocyst in the environmental 
condition. Generally these three infective stages are crescent – shaped cells, with a 
pointed apical end involves in cell invasion and a rounded posterior end. They are 
limited by pellicle as a membrane and cytoskeleton involved in the structural integrity 
and motility. They are built   in with nucleus, mitochondrion, Golgi complex, ribosomes 
and an endoplasmic reticulum. Tachyzoites are the rapid proliferative and dissemination 
form, which can invade all vertebral cell types by penetrating the plasma membrane or 
by phagocytosis and multiple rapidly causing cell rupture and continuous infection to 
neighbouring cells. Bradyzoites are the slow proliferative stage and form tissue cyst as a 
6 
 
result from the conversion of tachyzoites. These  cysts contain hundreds to thousands of 
densely packed bradyzoites that have a latent metabolism and remain intracellular for 
life span. Their high affinity towards central nervous system, muscular tissues including 
heart and skeletal muscle, eyes and placenta explains the clinical manifestation of these 
sites as tropism for reactivation of infection. Sporozoites are located in mature oocysts 
which has a multilayer wall for protecting the parasite from mechanical and chemical 
damage in the environment. As a result these oocysts can survive  for more than a year 













Figure 1.1: Three parasitic stages of Toxoplasma gondii. Microscopic examination of 
Tachyzoite (A), Bradyzoite in tissue (B), an unsporulated  (C) and sporulated oocysts 
(D) (Adopted from  Robert-Gangneux, F. and Dardé, M.L., 2012). 
 
 Life cycle of  T. gondii 
The life cycle alternates between definitive (sexual reproduction) and intermediate 
(asexual replication) hosts. Sexual reproduction occurs only in guts of felids (domestic 
and wild cats). After the ingestion of cysts present in an intermediate host or oocyst 
from the environment, the cell wall is destroyed by gastric enzyme and the parasite 
invades the intestinal mucosa of the definitive host. In the enterocytes the gametocytes 
are formed and fertilize into oocyst and excreted as unsporulated oocysts in cats feces. 
The shedding of oocysts begins 3 to 7 days after ingestion of tissue cysts and continues 
up to 20 days. Infected cat can shed more than 100 millions oocysts in their feces (Jones 
and Dubey, 2010). 
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Meanwhile within the intermediate hosts, there is only asexual reproduction occurs. 
After ingestion of oocyst from contaminated environment, sporozoites are released. 
Similarly, ingestion of uncooked or raw meat contains tissue cysts releases bradyzoites 
and these two forms of parasite penetrate the intestinal epithelium where they 
differentiate into tachyzoites which replicate rapidly and disseminate through the body. 
Once they reach the respective tropism sites, conversion to bradyzoites occurs as early 
as 7 to 10 days post infection and remain throughout life (Figure 1.2). 
 
Figure 1.2: Life cycle of Toxoplasma gondii. Shown are the biology, infection, and 
replication of the three infective stages of the parasites in their respective hosts. 






 Transmission  
The horizontal transmissions to humans are cause by ingestion of tissue cysts in infected 
meat or by ingestion of soil, water or food contaminated with sporulated cysts from 
environment. Another way is by solid organ transplantation , where by a cyst-containing 
organ from a donor to a non - immunised recipient in particular  heart transplant patient 
(Fernàndez-Sabé et al., 2011). Where else, vertical transmission occurs through 
tachyzoites colonized at placental tissue   to foetus by primary infection or reactivation 
of latent infection.    
 Clinical features of Toxoplasma infection 
In general, T. gondii infections are asymptomatic and self - limiting among healthy 
immunocompetent individuals, in others cases, patients may experience fever or 
cervical lymphadenopathy, sometimes associated with myalgia, asthenia, or other 
nonspecific clinical signs. However among pregnant women, new born, infants and 
immunocompromised patients the infection may cause severe clinical manifestation. 
 Manifestation during pregnancy and congenital toxoplasmosis  
Classically, congenital infection occurs only if a  pregnant women develops primary 
acquired infection during pregnancy or 8 weeks before conceiving. Placenta plays a 
major role as a barrier at the beginning of the gestation leading to less parasites 
transmission but later it becomes more permeable allowing transmission of 30% in 
second  trimester and 60 to 70%  third  trimester (Dunn et al., 1999). Congenital 
infection from a reactivation of chronic infection in an immunocompetent pregnant is a 
rare event. This condition is postulated due to decreased cellular response during 
pregnancy that interferes the parasitic control leading to increased risk of vertical 
transmission (Garweg et al., 2005). No doubt this phenomenon might attribute to 
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reinfection with exposure to different genotypes or reactivation of chronic infection 
(Elbez-Rubinstein et al., 2009). 
Foetal  infection during  early gestation are at high  risk of developing foetal anomaly  
such as miscarriage, stillbirth, intrauterine growth retardation and birth defect. Major 
squeal include mental retardation, seizures (80%), microcephalus and hydrocephalus 
(28%), deafness, and psychomotor deficiency (Remington et al., 2001). Eye lesion  is 
more severe in early pregnancy where microopthalmia, cataract, increase intraocular 
pressure, strabismus, optic neuritis, retinal necrosis, uveitis and retinochoroiditis can be 
observed (Delair et al., 2011; Roberts et al., 2001). Clinical manifestation during second 
trimester includes epilepsy, anaemia, thrombocytopenia induced petechial, hepatic 
disorder, severe sepsis, pneumonitis or retinochoroiditis (Remington et al., 2001). By 
contrast, late maternal infection mostly in third trimester results in subclinical 
toxoplasmosis in new born, sometimes goes unnoticed , but later in life may develop 
chorioretinitis (Montoya and Liesenfeld, 2004). 
  Role of placenta in T. gondii transmission and pathophysiology 
Placenta  is a key tissue in the mother-to-foetus relationship,  apart from  trophic role it 
also provides the tolerant immune microenvironment necessary for gestation (Entrican, 
2002). During primary infection, parasites cross intestinal barrier, invade monocytes in 
contact with lamina propria, disseminates throughout the body including placenta. 
Infection of placenta tissue leads to placentitis and subsequently  infect the trophoblast 
lining which interface with foetus compartment, proceeds to congenital infection. This 
important process has two main consequences, firstly placental infection may adversely 
affect this tenuous equilibrium between maternal and foetal compartments; and 
secondly placenta is directly involved in parasite transmission to the foetus.  
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By immune response, interferon ᵧ (IFN- ᵧ) produced by natural killer (NK) cells or 
CD8+ cytotoxic lymphocytes (CTL) directly controls both invasion of monocytes and 
trophoblasts by T. gondii and replication of the parasite in infected cells.  Massive IFN-ᵧ 
release has immunopathological effects, of which apoptosis of decidual cells and spiral 
artery dilation (Senegas et al., 2009). Some of these are essential immunomodulatory 
mechanisms that compensate for the Th-1 inflammatory cytokines induced by 
Toxoplasma, and could avoid foetal loss, particularly when infection occurs in early 
pregnancy. Human trophoblast cells produce interleukin 10 (IL-10) and transforming 
growth factor β1 (TGF-β1), which promote a Th-2 immune response to ensure 
maternal–foetal tolerance but induce a significant increase in both T. gondii intracellular 
replication and invasion (Barbosa et al., 2008).  IFNᵧ secretion induces intercellular 
adhesion molecule (ICAM)-1 up regulation on the trophoblast surface, enhancing 
adhesion of infected monocytes to the trophoblast cell surface. Infected trophoblast cells 
then lose the ability for apoptosis, which results in parasite persistence in placental 
tissues (Pfaff and Candolfi, 2008), and this can be a reservoir for immediate or delayed 
congenital infection. The strong expression of human leukocyte antigen-G (HLA-G) on 
trophoblast cells can inhibit lysis by maternal NK cells and can mediate suppression of 
the allocytotoxic T cell response against the foetus. HLA-G expression also drives 




Figure 1.3:Tentative scheme of the pathophysiological hypotheses controlling 
trophoblast–cell infection and transplacental transfer of Toxoplasma gondii.(Adopted 
from Robert-Gangneux et al., 2011) 
 
 Toxoplasmosis in immunocompromised patients 
Typically occurs as a reactivation of a chronic disease leading to life threatening 
condition. The immunocompromised patients consists of  HIV – infected patient, 
tuberculosis patient, on prolonged immune suppressive therapies such as Systemic 
Lupus Erythematous (SLE), haematological malignancy, non-communicable    disease 
such as diabetes mellitus and even old aged individuals. The major factor promoting to 
the reactivation of infection is profoundly impaired cellular immunity. In HIV – 
infected patients, the incidence is closely related to CD4 T cell counts, especially when 
count falls under100 cell/ul. Toxoplasmosis encephalitis (TE) most predominant 
manifestation with various symptoms, ranging from headache, lethargy, incoordination, 
or ataxia to hemiparesis, loss of memory, dementia, seizure usually associated with 
fever (Luft and Remington, 1992).  
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 Ocular toxoplasmosis 
T. gondii is the most common pathogen  of retinochroiditis leading to reccurent 
posterior uveitis worldwide (Butler et al., 2013). Common complaints are eye redness, 
blurring of vision and ocular pain. Chorioretinal lesion may develope from congenital or 
postnatal acquired infection and occur during the acute or latent stage of infection. 
Generally it is difficult to determine the infection was congenital or acquired with 
recurrences of chorioretinitis. Patients whom present with acute toxoplasmosis between 
the fourth and sixth decade of life, often have unilateral eye involvement, usually spare 
the macula with no scars. Whereas those acquired infection postnatally, often 
subclinical, may result in partial or complete loss of vision (Delair et al., 2008). By 
contrast in congenital infection, the chorioretinitis is bilateral and they might face severe 
complications such as optic nerve atrophy, glaucoma, cataract and retinal detachment. 
Among immunocompromised patients, ocular toxoplasmosis occur  with atypical and 
severe necrotizing form of retinochoroiditis (Antoniazzi et al., 2008). 
  Diagnostic methods 
There are several diagnostic approaches including detection of parasitic agent and 
Toxoplasma antibodies. Parasitic agents can be detected through histological 
identification, isolation from tissue culture and molecular technique by polymerase 
chain reaction (PCR). Whereas the serodiagnostic   test are mainly to detect different 
classes of antibodies or antigen. 
 Serology diagnosis  
Understanding the kinetic of antibody response is the basis of serological test. 
Interpretation of the results depends on patient’s immune background and disease 
setting followed by clinical signs. Many serology tests are to measure different types of 
antibody, including IgG, IgM, IgA, and IgE, which show unique increase or decrease 
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during the course of infection. The established serological methods available include  
Sabin – Feldman Dye test (SFDT), Indirect fluorescent Assay (IFA) agglutination tests, 
Enzyme-linked immunosorbent assays (ELISA) and Avidity of Toxoplasma  IgG.  In 
avidity of Toxoplasma IgG, a  high avidity ratio exclude a recent infection preceding 4 
months, test is performed during first trimester of pregnancy. Whereby, if index is  low 
or intermediate, the interpretation is ambivalent. This cannot exclude an infection 
acquired in the preceding 4 months, or prove that it is recent, unless the index is 
extremely low. Also  should be kept in mind that treatment delays IgG avidity 
maturation (Meroni et al., 2009). 
  Kinetic of antibody responses 
T. gondii-specific IgM antibodies rises from day 5  to weeks following acute infection 
(Paquet et al., 2013) peaks at 2 months and disappear within 6-9 months, more rapidly 
than IgG. A positive IgM result indicates an early, acute or a recent Toxoplasma 
infection. In recent infection  there will be presence of persistent IgM (Meek et al., 
2001; Montoya and Liesenfeld, 2004). IgM antibodies can persist over years without 
any clinical significance and thus hamper the interpretation of test results especially in 
case of pregnancy screening (Remington et al., 2001; Wong and Remington, 1994) T. 
gondii-specific IgG antibody  are detectable within 1 or 2 weeks after infection, peaks 
within 12 weeks to 6 months and persist for decades (Paquet et al., 2013). (Figure 1.4). 
A positive result indicates a previous exposure (latent infection) and provide immunity 
to reinfection unless from a different genotype and virulence genes.  It may also indicate 
recent or reactivation of latent  infection. In case of recent or reactivation of  infection 
usually a significant rise or 4 fold titer  in IgG antibody level can be expected in serial 
samples obtained in  2 – 3  weeks apart (Montoya and Liesenfeld, 2004).  Passive 
immunity is detection of IgG antibody in newborn or infant, is from mother and may 
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persist up to 6 – 12 months. The IgG antibody titer reduces to 50%  every month till 6 
month or 12 months of age. A negative IgG antibody at 1 year of age essentially rules 
out congenital toxoplasmosis (Lago et al., 2014). In recent years, IgE and IgA antibody 
has proved a better age of infection especially in new born because they are specific 
with no cross immunity from  mother. However, they are produced during first week of 
infection and disappears early. 
Reinfection during pregnancy are associated with exposure to a large number of 
parasites, more virulent strain or  a different genotype (Lebas et al., 2004). Where by  
reactivation occurs  from a latent infection. Both these conditions have been reported in 
an immunocompetent mother which  later caused congenital infection to her new born. 
The serological profile of  reinfection is by detecting (IgM and /or IgA antibodies, and 
high IgG level) compared to reactivation (no IgM and /or IgA antibodies, and high IgG 
level) (Andrade et al., 2010).  
Figure 1.4:Toxoplasma infection serological profile (Adopted from Elecsys Toxo IgG, 





1.3.6.3. Sabin – Feldman dye test (SFDT) 
Sabin – Feldman dye test (SFDT) is the first assay developed and still considered as the 
gold standard with high sensitivity and specificity. This test is applied based on 
incubation of  live tachyzoites on the slide with patients serum and complement.  If the 
serum contains specific antibodies against T. gondii, the coated tachyzoite will be lysed 
by the complement system and fail to stain with dye  methylene blue. Finally  the 
stained and  unstained tachyzoites are counted and used as end-point titer. The 
limitation for this test is application of live tachyzoites which is considered as biohazard 
and fails to determine the stage of infection (Udonsom et al., 2010). 
 Indirect fluorescent assay (IFA) 
This method is applied based on killed tachyzoites fixed on a glass slide to react with 
the antibody in the serum. The detection of this reaction is by fluorescence – labelled  
anti human IgG and IgM antibodies and reviewed under a fluorescence microscope. 
This test is simple, safe and inexpensive but it is operator dependent. There are also 
possibilities of false positive results in cases of patients with rheumatoid factors or 
antinuclear antibodies (Rorman et al., 2006). 
 Agglutination tests 
The available tests are direct agglutination test (DAT), indirect hemagglutination test 
(IHAT)  and latex agglutination test (LAT). Development of these tests are to identify 
antibodies against T. gondii. DAT starting with coating of microtiter plates containing 
formalinized Toxoplasma tachyzoites will agglutinate if antibodies are present in the 
diluted patients serum. In IHAT, sensitised red blood cells (RBCs) are used that shows 
agglutination if serum are positive with anti – T. gondii antibodies (Liu et al., 2015). In 
LAT, tachyzoites are fixed to latex beads and visible flocculation reveals positive serum 
containing specific IgG antibody. The agglutination test are generally simple and 
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inexpensive but there a tendencies for false positive results  to occur especially in 
immunocompromised individual. 
 Enzyme – linked immunosorbent assay (ELISA)  
The principle of this assay is a  microtiter plate is coated with antigens, and diluted sera 
are applied. The anti – Toxoplasma antibodies will bind to the antigen and detected by 
secondary antibody. Unbound reagents are washed and substrate is added colour 
reaction occurs which correlates with the quantity of the antibody. The determination of 
results depends on optic density of the serum. This test is highly sensitive, measures 
quantitative and semiquantitative  antibody, detects IgG, IgM, IgA and IgE antibodies 
and applied as a large scale of samples in short duration (Sudan et al., 2013). In current 
settings, the latest generation of ELISA, electrochemiluminescence immunoassay  
“ECLIA”is applied in most laboratories as a screening tool for Toxoplasma infection. 
The initial principle is similar to ELISA but the end result is measured with a cell  that 
uses electrodes and magnet to gather the bound immunocomplexes. Finally application 
of a defined voltage induces the electrochemiluminescent reaction and the resulting 
light emission is measured directly by the photomultiplier.  
A study conducted by the new Roche Elecsys Toxo IgG and IgM immunoassay was 
compared with Sabin–Feldman dye test and immunosorbent agglutination assay-IgM as 
a reference test. Single serum samples were analysed from 927 pregnant women, 
including 100 negative, 706 chronic, and 121 acute infections. The combination of both 
Elecsys IgG and Ig M assays demonstrated high sensitivity and specificity of 97.1% and 
100.0%, respectively, and a positive and negative predictive value of 100.0% and 
81.3%, respectively (Prusa et al., 2010). 
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 Parasite isolation 
Isolation of T. gondii  from blood, body fluids and tissue always indicate acute 
infection. Isolation is by inoculation of the parasites from patients sample in the tissue 
cultures or laboratory animals. In mice, the test is performed by injecting the clinical 
samples either intraperitoneally or subcutaneously. The mice will be subjected for 
serological test after 3 to 6 weeks to detect the presence of anti T.gondii antibodies. 
Tissues from positive antibodies will be tested with  PCR or microscopic examination  
to look for cysts for final confirmation (Hill and Dubey, 2002). 
 Histologic diagnosis 
Demonstration of  tachyzoites in tissue or smears of body fluids establish the diagnosis 
of acute infection. Conventional staining is difficult to demonstrate tachyzoites, 
therefore the immunoperoxidase technique with antisera is applied successfully to detect 
the parasite in toxoplasmosis encephalitis cases of HIV patients (Montoya, 2002). 
 Molecular diagnosis 
PCR amplification for detection of T. gondii DNA in body fluids and tissues are used to 
diagnose congenital, ocular, cerebral and disseminated toxoplasmosis. The most popular 
used gene is the 35 – fold repetitive gene B,  one of the first gene used in the PCR 
detection of T.gondii (Sarkari et al., 2014). PCR has evolved in the diagnosis of 
intrauterine Toxoplasma infection by early detection in placenta tissue or amniotic 
fluids and helped to guide for prompt treatment and avoid  unnecessary  invasive 
procedures (Montoya, 2002). Amniotic fluids from amniocentesis   is the cornerstone 
for diagnosis of congenital toxoplasmosis. If maternal primary infection is suspected 
and abnormal ultrasound findings were diagnosed (intracranial calcification, 
microcephaly, hydrocephalus, ascites, hepatosplenomegaly or severe intrauterine 
growth retardation), PCR should be offered to identify Toxoplasma infection in the 
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amniotic fluid. This procedure is not performed at less than 18 weeks gestation because 
of high rate of false positive results, nevertheless should be done not less than 4 weeks 
after time of suspected maternal infection (Paquet et al., 2013). Performance of 
amniocentesis after 18 weeks has sensitivity of  91%, specificity 96 % (Romand et al., 
2001).          
 Treatment 
Treatment in immunocompetent pregnant women with previous infection with T. gondii 
should not be necessary. Women who are immunosuppressed or HIV-positive should be 
offered screening because of the risk of reactivation and toxoplasmosis encephalitis. A 
non-pregnant woman, diagnosed with an acute toxoplasmosis  should be counselled to 
wait 6 months before attempting to become pregnant. Each case should be considered 
separately in consultation with an expert. The existing indication for treatment in 
pregnant women is to achieve two goals. Firstly, if maternal infection occurred but 
foetus is not infected, aimed at preventing vertical transmission, before foetal infection. 
Spiramycin, a macrolide, does not readily cross the placenta,  therefore is not reliable 
for treatment of foetal infection. As a foetal prophylaxis,  is used to prevent spread of 
organisms across the placenta (Goldstein et al., 2008). Secondly if foetal infection has 
been confirmed or is highly suspected by amniotic fluid PCR or foetal ultrasound, 
pyrimethamine and sulfadiazine is indicated. Pyrimethamine is a folic acid antagonist 
acts synergistically with sulfonamides. This drug not be used in the first trimester, 
potentially teratogenic and a reversible dose related depression of the bone marrow and 
therefore must be combined with folinic acid. The combination of pyrimethamine and 
sulfadiazine results in a significant decrease in disease severity. Neonates with 
congenital toxoplasmosis, even asymptomatic at birth should be treated early to reduce 
long term squeal (Paquet et al., 2013) (Figure 1.5). 
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In patients with AIDS whom developed reactivation of cerebral toxoplasmosis, CD4 
cell count of < 100 cells/mm3 has a strong association as a prognostic marker in 
progression of the disease, especially with other opportunistic infection. Toxoplasmosis 
encephalitis is a preventable disease when adequate chemoprophylaxis of trimethoprim-
sulfamethoxazole or dapsone-pyrimethamine plus folinic acid is administered (Passos et 
al., 2000).  
The diagnosis for retinochoroiditis depends on an accurate opthalmological examination 
which shows typical of white focal lesion associated with a vitreous inflammatory 
reaction and Toxoplasma seropositivity. This indicates for treatment and further 
confirmed with therapeutic response (Robert-Gangneux and Dardé, 2012). Intravitreous 
clindamycin with dexamethasone seems to be as effective as systemic treatments, where 
as other preferred oral antibiotic would be trimethoprim-sulfamethoxazole, 





Figure 1.5: Treatment approach for pregnant women suspected or confirmed to have 
toxoplasmosis acquired during gestation. (Adopted from Goldstein, E. J., Montoya, J. G. 
& Remington,J. S. 2008).  
 
 Prevention and control measures 
Various efforts have been taken to reduce the burden of Toxoplasma infection among all 
population. Good hygiene measures such as hand washing after contact with raw meat, 
after gardening or other external activity in contact with soil and close contact with cats. 
Thorough washing of fruits and vegetables is strongly advised and cat litter box need to 
be changed every 2 days. Primary care is the first line to explain the preventive 
measures to pregnant women or those  plan to be pregnant. Besides counselling, written 
information is helpful to reduce congenital toxoplasmosis. Based on a  survey regarding 
knowledge and practice on Toxoplasma infection in pregnant women from Malaysia, 
Philippines, and Thailand, only 11% of these pregnant women had read, heard, or seen 
information regarding toxoplasmosis and 3.5% of them were aware of being tested for 
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the infection (Andiappan et al., 2014). Screening for pregnant women and neonate is 
implemented in many European countries. Hence the decisions on implementation of 
screening in a country are considered based on prevalence data, disease burden, 







































Figure 1.6: Conceptual framework for case selection process 
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 General objectives 
To describe the clinical manifestation and determine the seroprevalance classification of 
infection among the selected populations, validity of the test and percentage of patient 
on treatment after first and paired serum sample. 
 Specific objectives 
1. To describe the clinical manifestation of Toxoplasma infection among pregnant 
women, new born, infant, child above 1 year old, immunocompromised and immuno 
- competent patients. 
2. To determine  seroprevalence  of  early, acute, reactivation, recent, latent, passive 
immunity from mother and possible congenital infection with paired serum sample 
using Elecsys IgM / IgG assay among  pregnant women , new born, infant, child 
above 1 year old, immunocompromised and  immunocompetent patients. 
3. To determine the validity of paired serum sample  to diagnose Toxoplasma infection 
by calculating the sensitivity, specificity, PPV, NPV and  ROC curve analyses in 
clinically confirmed cases ( by gold standard). 
4. To describe the percentage of patient on treatment after the first and paired serum 
sample.  
 Research hypothesis 
The classification of Toxoplasma infection into early , acute, reactivation, recent , latent,  
passive immunity from mother and possible congenital infection can be established by 
using paired serum sample of  Toxoplasma IgM and IgG antibody titer in pregnant 
women , new born, infant, child above 1 year old, immunocompromised and 
immunocompetent  patients. 
